Effective May 28, 2019, Protagonist Therapeutics, Inc. appointed Donald Kalkofen as Chief Financial Officer to serve as the company's principal financial officer and principal accounting officer. Dinesh V. Patel the company's President and Chief Executive Officer, had served as interim principal financial officer from January 11, 2019 until the Effective Date and had served as interim principal accounting officer from March 20, 2019 until the Effective Date. Mr. Kalkofen, age 55, had served in a consulting capacity as the Company's Senior Advisor, Finance since February 11, 2019 until his appointment as Chief Financial Officer, and previously served in a consulting capacity as Interim Controller of the Company from May 2018 to June 2018.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.15 USD | +1.59% | -7.43% | +22.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.76% | 162.53Cr | |
+43.36% | 5.81TCr | |
-5.31% | 4.05TCr | |
+37.52% | 3.9TCr | |
+14.75% | 2.67TCr | |
-12.56% | 2.66TCr | |
-22.45% | 1.9TCr | |
+0.04% | 1.22TCr | |
+25.12% | 1.2TCr | |
+26.04% | 1.19TCr |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics, Inc. Announces the Appointment of Donald Kalkofen as Chief Financial Officer and Principal Accounting Officer, Effective May 28, 2019